National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018
Tanja Y Walker, Laurie D Elam-Evans, David Yankey, Lauri E Markowitz, Charnetta L Williams, Benjamin Fredua, James A Singleton, Shannon Stokley, Tanja Y Walker, Laurie D Elam-Evans, David Yankey, Lauri E Markowitz, Charnetta L Williams, Benjamin Fredua, James A Singleton, Shannon Stokley
Abstract
The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11-12 years to protect against certain diseases, including human papillomavirus (HPV)-associated cancers, meningococcal disease, and pertussis (1). A booster dose of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended at age 16 years, and serogroup B meningococcal vaccine (MenB) may be administered to persons aged 16-23 years (1). To estimate vaccination coverage among adolescents in the United States, CDC analyzed data from the 2018 National Immunization Survey-Teen (NIS-Teen) which included 18,700 adolescents aged 13-17 years.* During 2017-2018, coverage with ≥1 dose of HPV vaccine increased from 65.5% to 68.1%, and the percentage of adolescents up-to-date† with the HPV vaccine series increased from 48.6% to 51.1%, although the increases were only observed among males. Vaccination coverage increases were also observed for ≥1 MenACWY dose (from 85.1% to 86.6%) and ≥2 MenACWY doses (from 44.3% to 50.8%). Coverage with tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap) remained stable at 89%. Disparities in coverage by metropolitan statistical area (MSA)§ and health insurance status identified in previous years persisted (2). Coverage with ≥1 dose of HPV vaccine was higher among adolescents whose parents reported receiving a provider recommendation; however, prevalence of parents reporting receiving a recommendation for adolescent HPV vaccination varied by state (range = 60%-91%). Supporting providers to give strong recommendations and effectively address parental concerns remains a priority, especially in states and rural areas where provider recommendations were less commonly reported.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Figures
References
- Robinson CL, Bernstein H, Romero JR, Szilagyi P. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2019. MMWR Morb Mortal Wkly Rep 2019;68:112–4. 10.15585/mmwr.mm6805a4
- Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2017. MMWR Morb Mortal Wkly Rep 2018;67:909–17. 10.15585/mmwr.mm6733a1
- Kornides ML, McRee AL, Gilkey MB. Parents who decline HPV vaccination: who later accepts and why? Acad Pediatr 2018;18(2S):S37–43. 10.1016/j.acap.2017.06.008
- Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine 2016;34:1187–92. 10.1016/j.vaccine.2016.01.023
- Boyd ED, Phillips JM, Schoenberger YM, Simpson T. Barriers and facilitators to HPV vaccination among rural Alabama adolescents and their caregivers. Vaccine 2018;36:4126–33. 10.1016/j.vaccine.2018.04.085
- Radecki Breitkopf C, Finney Rutten LJ, Findley V, et al. Awareness and knowledge of human papillomavirus (HPV), HPV-related cancers, and HPV vaccines in an uninsured adult clinic population. Cancer Med 2016;5:3346–52. 10.1002/cam4.933
- Bernstein HH, Bocchini JA Jr; Committee on Infectious Diseases. The need to optimize adolescent immunization. Pediatrics 2017;139:e20164186. 10.1542/peds.2016-4186
- Senkomago V, Henley J, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus–attributable cancers—United States, 2012–2016. MMWR Morb Mortal Wkly Rep 2019;68:724–8.
- McClung NM, Lewis RM, Gargano JW, Querec T, Unger ER, Markowitz LE. Declines in vaccine-type human papillomavirus prevalence in females across racial/ethnic groups: data from a national survey. J Adolesc Health. In press 2019.
- Gargano JW, Park IU, Griffin MR, et al.; HPV-IMPACT Working Group. Trends in high-grade cervical lesions and cervical cancer screening in 5 states, 2008–2015. Clin Infect Dis 2019;68:1282–91. 10.1093/cid/ciy707
Source: PubMed